Meet an Unreasonable Venture
OriCiro
Creating a better bioeconomy with innovative genome technologies.
OriCiro is a pioneer of cell-free genome technology, providing a powerful tool for research and development aimed at unlocking the possibility of synthetic biology. The company’s proprietary technology focuses on the development and commercialization of cell-free synthesis and amplification technologies of large DNA molecules aiming to replace conventional cell-based methodology by not only streamlining current research processes, but also widening the scope of genomics research significantly. The company also owns a suite of genome technologies, including the assembly of DNA fragments and genome editing. Synthetic biology, through which new medicines and useful proteins can be produced more efficiently by modified and/or synthesized genomes — is developing rapidly worldwide. OriCiro’s technologies have potential markets in a variety of industries including the pharmaceutical, diagnostic, industrial biotech, food, and agricultural sectors.
OriCiro has been acquired.
Press Mentions
January 4, 2023
Moderna to Acquire OriCiro Genomics
OriCiro's synthetic biology and enzyme technologies will support Moderna's expanding portfolio of therapeutics and vaccines Acquisition will bolster Moderna's suite of platform technologies...
Read more »More Ventures in Health
Get the Unreasonable Newsletter
Get monthly updates on OriCiro and over 398 other ventures working to solve the world's toughest problems.